review · International Journal of Medical Sciences and Pharma Research
Sickle cell anaemia is driven by abnormal haemoglobin S, which causes red blood cells to sickle and trigger painful vaso-occlusive crises that can lead to organ damage. Co-existing haemoglobin variants alter the severity and frequency of these crises by changing cellular morphology, oxygen affinity, and inflammatory pathways. Haemoglobin C increases cell rigidity and promotes adhesion to the blood vessel endothelium, raising the likelihood of blockages. In contrast, haemoglobin E possesses a higher oxygen affinity that can reduce cell sickling. Both variants also affect inflammatory responses, including leukocyte recruitment and endothelial activation, which are central to vaso-occlusive processes. Understanding these specific variant interactions provides a basis for tailoring individualised therapies, including hydroxyurea regimens and emerging gene therapies, to match a patient's distinct profile.
Sickle cell anaemia causes severe pain and long-term organ damage through recurring vascular blockages. Because different haemoglobin variants alter the behaviour of red blood cells in contrasting ways, recognising a patient's specific genetic variant helps clinicians predict disease severity and select more effective, personalised interventions.
The insights support the development of personalised therapeutic approaches, potentially guiding how clinicians and pharmaceutical developers deploy treatments like hydroxyurea or tailor emerging gene therapies to specific genetic profiles. As this review synthesises biological mechanisms, practical application remains at an early conceptual stage pending targeted clinical trials and validation.
AI-generated from the published abstract. Always read the original work before citing.
Sickle cell anemia (SCA) is a genetic disorder characterized by the presence of abnormal hemoglobin S (HbS), leading to the sickling of red blood cells (RBCs) and subsequent vaso-occlusive crises (VOCs). These crises are responsible for acute pain episodes and potential organ damage, significantly affecting the quality of life for individuals with SCA. The clinical presentation of SCA can be modified by various hemoglobin variants, including hemoglobin C (HbC) and hemoglobin E (HbE), which influence the severity and frequency of VOCs through alterations in red blood cell morphology, oxygen affinity, and inflammatory responses. The presence of hemoglobin variants can affect red blood cell rigidity and aggregation, leading to enhanced vascular occlusion and increased susceptibility to VOCs. Hemoglobin C, for instance, results in more rigid RBCs that readily adhere to the endothelium, while hemoglobin E may reduce the degree of sickling due to its higher oxygen affinity. Furthermore, these variants can modulate the inflammatory response, influencing the recruitment of leukocytes and the activation of endothelial cells, thereby contributing to the overall pathophysiology of VOCs in SCA. Individualized treatment approaches, such as hydroxyurea therapy and emerging gene therapies, can be tailored based on the specific hemoglobin variant present in the patient. Continued research is crucial to elucidate the complex interactions between hemoglobin variants and VOCs, ultimately leading to improved patient outcomes and enhanced quality of life for those affected by sickle cell anemia. Keywords: Sickle cell anemia, hemoglobin variants, vaso-occlusive crises, hemoglobin S, hemoglobin C, hemoglobin E, vascular occlusion, inflammation, red blood cells, therapeutic strategies
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.22270/ijmspr.v10i2.104
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
